Active Ingredient History

  • Now
Insulin glulisine is a rapid-acting modified form of medical insulin that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. It was developed by Sanofi-Aventis and approved for marketing by the FDA in 2004; it is sold under the trade name Apidra. When injected subcutaneously, it appears in the blood earlier than human insulin. When used as a meal time insulin, the dose is to be administered within 15 minutes before or 20 minutes after starting a meal. Intravenous injections may also be used for extreme hyperglycemia, but must be performed under the supervision of a medical professional.   Wikipedia

More Chemistry
  • Mechanisms of Action:
  • Multi-specific: No
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$11.0350 - $42.6400


$18.4211 - $31.7951
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

apidra | apidra solostar | b3-lysyl-b29-glutamylinsulin | glulisine apidra | glulisine insulin | hmr 1964 | hmr-1964 | ins apidra | ins apidra opticlik | ins apidra optiset | ins apidra solostar | insulin apidra | insulin glulisine | insulin glulisine (genetical recombination) | insulin glulisine (rdna origin) | insulin glulisine [rdna origin] | insulin glulisine recombinant | insulin glulisine (recombinant dna origin) | insulin, lys(b3)-glu(b29)- | insulin, lysyl(b3)-glutamyl(b29)-


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue